Natamycin and azole drugs: clinical and laboratory efficiency in nonpregnant women with vulvovaginal c

Authors

  • Е. Т. Мальбахова Scientific Center for Obstetrics, Gynecology and Perinatology named after V.I. Kulakov Russia, Russian Federation
  • В. Г. Арзуманян Research Institute of Vaccines and Sera named after I.I. Mechnikov of RAMS, Russian Federation
  • Л. М. Комиссарова Scientific Center for Obstetrics, Gynecology and Perinatology named after V.I. Kulakov of Health Ministry of Russia, Russian Federation
  • О. Р. Баев Scientific Center for Obstetrics, Gynecology and Perinatology named after V.I. Kulakov of Health Ministry of Russia, Russian Federation

DOI:

https://doi.org/10.18370/2309-4117.2012.6.56-62

Keywords:

АМП, ВВК, дрожжи, Пимафуцин, противогрибковые препараты

Abstract

For the period 2008-2010 examined 51 women with VVC. Control group consist of 48 women with VVC surveyed in 1999-2000, and 114 patients with atopic dermatitis. It was found that the severity of the VVC in chronic recurrence course of the disease is 1,6 times higher than in the initial acute course. The sensitivity of isolates obtained from women with VVC for 10 years has changed: to azole decreased in 1,4-1,5 times, and to natamycin increased in 1,2 times. The same trend is true for the yeast strains isolated from patients with atopic dermatitis. In acute VVC it was enough to use a drug Pimafucin in suppositories at least 6 days, and in patient with chronic recurrent course preferable longer course of therapy for 9 days with the addition of cream and tablet forms of the drug

References

  1. Sobel J.D. Recurrent vulvovaginal candidiasis advanses in patogenesis and treatment. 3rd Trends in Medical Mycology. Turin, 2007.
  2. Климко Н.Н., Мирзабалаева А.К., Долго-Сабурова Ю.В., Жорж О.Н., Босак И.А., Выборнова И.В. Изучение эффективности и безопасности препарата «Ливарол», вагинальные суппозитории, в купировании рецидива хронического рецидивирующего кандидоза гениталий, обусловленного не-albicans Candida spp. Отчет. СПб МАПО Росздрава, кафедра клинической микологии, аллергологии и иммунологии, НИИ им. М.М. Кашкина, 2007.
  3. Прилепская В.Н. Вульвовагинальный кандидоз: современные методы лечения. В кн.: Практическая гинекология. Под ред. Кулакова В.И., Прилепской В.Н. – М.: МЕДпресс-информ; 2006.
  4. Jawetz E., Melnick J.L., Adelberg E.A. Review of medical microbiology. Lange Medical Publication, 1980; 2: 224-69.
  5. Ahearn D.G., Simmons R.B., Malassezia Baillon. The Yeasts, A Taxonomic study. Ed. by Kurtsman C.P., Fell J.W. Elsevier, 1998; 782.
  6. Ghannoum M.A., Rice L.B. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clinical Microbiology Reviews. 1999; 12 (4): 501-17.
  7. Арзуманян В.Г., Зайцева Е.В., Кабаева Т.И., Темпер Р.М. Оценка стафилококковой и нелипофильной дрожжевой микрофлоры кожи у больных с кожной патологией при контактном способе посева. Вестник дерматологии и венерологии. 2004; 6: 3-6.
  8. Aрзуманян В.Г., Магаршак О.О., Семенов Б.Ф. Дрожжеподобные грибы у пациентов с аллергическими заболеваниями: видовое разнообразие и чувствительность к противогрибковым препаратам. Бюллетень экспериментальной биологии и медицины. 2000; 6: 704-8.
  9. Арзуманян В.Г. Минимальные ингибирующие концентрации некоторых противогрибковых препаратов для клинически значимых базидиомицетных дрожжей. Антибиотики и химиотерапия. 2002; 2: 7-10.
  10. Сухих Г.Т., Ванько Л.В. Иммунология беременности. М.: Издательство РАМН; 2003; 91-114.
  11. de Carvalho R.J.V, Cunha C.M., Silva D.A., de Oliveira, Sopelete M.C. et al. Ig A, Ig E and Ig G subclasses to Candida albicans in serum and vaginal fluid from patients with vulvovaginal candidiasis. Revista Da Associacao Medica Brasileira. 2003; 49 (4): 434-8.
  12. Mestecky J., Moldoveanu Z., Russell M.W. Immunologic uniqueness of the genital tract: challenge for vaccine development. American Journal of Reproductive Immunology. 2005; 53 (5): 208-14.
  13. Valore E.V., Park C., Igreti S.L., Ganz T. Antimicrobial components of vaginal fluid. J Obstet Gynecol. 2002; 187: 561-8.
  14. Valore E.V., Wiley D.J., Ganz T. Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. Infection and Immunity. 2006; 74 (10): 5693-702.
  15. Арзуманян В.Г., Мальбахова Е.Т., Комиссарова Л.М., Сердюк О.А., Касабулатов Н.М. Местный противогрибковый иммунитет при вульвовагинальном кандидозе у беременных. Акушерство и гинекология. 2008; 6: 23-6.

Downloads

Published

2012-08-14

How to Cite

Мальбахова, Е. Т., Арзуманян, В. Г., Комиссарова, Л. М., & Баев, О. Р. (2012). Natamycin and azole drugs: clinical and laboratory efficiency in nonpregnant women with vulvovaginal c. REPRODUCTIVE ENDOCRINOLOGY, (6), 56–62. https://doi.org/10.18370/2309-4117.2012.6.56-62

Issue

No. 6 (2012)

Section

Inflammatory diseases

License

Copyright (c) 2014 Е. Т. Мальбахова, В. Г. Арзуманян, Л. М. Комиссарова, О. Р. Баев

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.